N-(2-amino-3-fluoro-2-methylpropyl)-8-[(2,6-difluorophenyl)methoxy]-6-(fluoromethyl)-2-methylimidazo[1,2-a]pyridine-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: N-(2-amino-3-fluoro-2-methylpropyl)-8-[(2,6-difluorophenyl)methoxy]-6-(fluoromethyl)-2-methylimidazo[1,2-a]pyridine-3-carboxamide
• 化学式: C₂₁H₂₂F₄N₄O₂
• 分子量: 438.4
• InChiKey: YTKQVOJCAYMBKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  81.6
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20140179672A1

  公开（公告）日：2014-06-26

  The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新型取代的咪唑并[1,2-a]吡啶-3-羧酰胺，其制备过程，它们单独或与其他药物组合用于治疗和/或预防疾病，以及它们用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20150274719A1

  公开（公告）日：2015-10-01

  The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新型取代的咪唑并[1,2-a]吡啶-3-羧酰胺，其制备方法，其单独或与其他药物联合用于治疗和/或预防疾病，以及其用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US10662185B2

  公开（公告）日：2020-05-26

  The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides of the general formula (I) to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及通式 (I) 的新型取代咪唑并[1,2-a]吡啶-3-甲酰胺 它们的制备工艺，它们在治疗和/或预防疾病方面的单独用途或组合用途，以及它们在制备治疗和/或预防疾病（尤其是治疗和/或预防心血管疾病）的药物方面的用途。
• Combination containing SGC stimulators and mineralocorticoid receptor antagonists
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US10918639B2

  公开（公告）日：2021-02-16

  The present invention relates to the combination of stimulators of soluble guanylate cyclase (sGC stimulators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.

  本发明涉及可溶性鸟苷酸环化酶刺激剂（sGC 刺激剂）与矿质皮质激素受体拮抗剂（MR 拮抗剂）的组合，以及该组合在治疗和/或预防心脏和心血管疾病、肾脏和心肾疾病、肺部和心肺疾病以及治疗和/或预防纤维化疾病方面的用途。
• Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US11166932B2

  公开（公告）日：2021-11-09

  The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonists and the use thereof for the treatment and/or prophylaxis of cardiovascular disorders, for example heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, lung disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for the treatment and/or prophylaxis of fibrotic disorders and other disease symptoms (e.g. end organ damage affecting the brain, kidney or heart).

  本发明涉及与中性内肽酶抑制剂和/或血管紧张素AII拮抗剂联合使用的可溶性鸟苷酸环化酶刺激剂和激活剂，以及将其用于治疗和/或预防心血管疾病，例如射血分数保留型心力衰竭或射血分数降低型心力衰竭、肾脏疾病，例如慢性肾衰竭、泌尿系统疾病、肺部疾病、中枢神经系统疾病，用于调节脑灌注，例如在血管性脑痴呆的情况下，用于治疗和/或预防纤维化疾病和其他疾病症状（例如：影响神经系统的终末器官损伤）。如影响大脑、肾脏或心脏的终末器官损伤）。